Glesatinib
Overview[edit]
Glesatinib is a small molecule tyrosine kinase inhibitor that is being investigated for its potential use in the treatment of various types of cancer. It specifically targets the MET receptor tyrosine kinase, which is often overexpressed or mutated in certain cancer types, leading to uncontrolled cell growth and proliferation.
Mechanism of Action[edit]
Glesatinib works by inhibiting the activity of the MET receptor. The MET receptor is a proto-oncogene that, when activated, can trigger a cascade of downstream signaling pathways involved in cell growth, survival, and metastasis. By blocking MET, glesatinib aims to halt the progression of cancer by preventing these signals from being transmitted.
Clinical Development[edit]
Glesatinib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with MET-positive cancers. These trials are crucial for determining the appropriate dosing, potential side effects, and overall therapeutic benefit of the drug.
Potential Indications[edit]
The primary focus of glesatinib research is on non-small cell lung cancer (NSCLC) and other solid tumors that exhibit MET dysregulation. Researchers are also exploring its use in combination with other therapies to enhance its anticancer effects.
Side Effects[edit]
As with many targeted therapies, glesatinib may cause a range of side effects. Commonly reported side effects include fatigue, nausea, and diarrhea. More serious adverse effects may occur, necessitating close monitoring of patients during treatment.
Future Directions[edit]
Ongoing research aims to better understand the role of MET in cancer and to identify biomarkers that can predict response to glesatinib. This will help in personalizing treatment plans and improving outcomes for patients.
Related Pages[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
